X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs AUROBINDO PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES AUROBINDO PHARMA DIVIS LABORATORIES/
AUROBINDO PHARMA
 
P/E (TTM) x 38.2 19.3 198.4% View Chart
P/BV x 6.2 4.8 127.8% View Chart
Dividend Yield % 0.7 0.3 224.9%  

Financials

 DIVIS LABORATORIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
AUROBINDO PHARMA
Mar-17
DIVIS LABORATORIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,142895 127.6%   
Low Rs533622 85.7%   
Sales per share (Unadj.) Rs146.6254.6 57.6%  
Earnings per share (Unadj.) Rs33.039.3 84.1%  
Cash flow per share (Unadj.) Rs38.446.6 82.5%  
Dividends per share (Unadj.) Rs10.002.50 400.0%  
Dividend yield (eoy) %1.20.3 362.3%  
Book value per share (Unadj.) Rs222.8160.0 139.3%  
Shares outstanding (eoy) m265.47585.88 45.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.73.0 191.8%   
Avg P/E ratio x25.319.3 131.3%  
P/CF ratio (eoy) x21.816.3 133.9%  
Price / Book Value ratio x3.84.7 79.3%  
Dividend payout %30.36.4 475.6%   
Avg Mkt Cap Rs m222,318444,390 50.0%   
No. of employees `00010.814.0 77.0%   
Total wages/salary Rs m4,56117,678 25.8%   
Avg. sales/employee Rs Th3,616.010,667.8 33.9%   
Avg. wages/employee Rs Th423.81,264.3 33.5%   
Avg. net profit/employee Rs Th814.91,645.8 49.5%   
INCOME DATA
Net Sales Rs m38,915149,157 26.1%  
Other income Rs m1,1341,159 97.9%   
Total revenues Rs m40,049150,316 26.6%   
Gross profit Rs m12,61734,343 36.7%  
Depreciation Rs m1,4254,276 33.3%   
Interest Rs m13667 2.0%   
Profit before tax Rs m12,31330,558 40.3%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,5437,597 46.6%   
Profit after tax Rs m8,77023,012 38.1%  
Gross profit margin %32.423.0 140.8%  
Effective tax rate %28.824.9 115.8%   
Net profit margin %22.515.4 146.1%  
BALANCE SHEET DATA
Current assets Rs m45,35192,062 49.3%   
Current liabilities Rs m6,50766,223 9.8%   
Net working cap to sales %99.817.3 576.2%  
Current ratio x7.01.4 501.3%  
Inventory Days Days127106 119.5%  
Debtors Days Days9568 140.6%  
Net fixed assets Rs m21,16062,919 33.6%   
Share capital Rs m531586 90.6%   
"Free" reserves Rs m58,62593,133 62.9%   
Net worth Rs m59,15693,719 63.1%   
Long term debt Rs m01,814 0.0%   
Total assets Rs m67,832162,494 41.7%  
Interest coverage x926.846.8 1,980.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.9 62.5%   
Return on assets %12.914.6 88.9%  
Return on equity %14.824.6 60.4%  
Return on capital %20.832.7 63.6%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35975,838 42.7%   
Fx outflow Rs m9,04230,224 29.9%   
Net fx Rs m23,31745,613 51.1%   
CASH FLOW
From Operations Rs m7,75932,786 23.7%  
From Investments Rs m-4,783-17,870 26.8%  
From Financial Activity Rs m-3,142-19,153 16.4%  
Net Cashflow Rs m-166-4,239 3.9%  

Share Holding

Indian Promoters % 52.0 54.1 96.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 8.0 148.4%  
FIIs % 19.0 27.7 68.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.2 168.6%  
Shareholders   31,796 69,601 45.7%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 18, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS